Selma Ugurel, Nessr Abu Rached, Thilo Gambichler, Miriam Mengoni, Thomas Tüting, Jessica C. Hassel, Robin Reschke, Georg C. Lodde, Jan-Malte Placke, Dirk Schadendorf, Lydia Reinhardt, Alexander Kreuter, Martin Gschnell, Jochen Utikal, Michael Erdmann, Pia Dücker, Doris Helbig, Cindy Franklin, Christoffer Gebhardt, Gabriela Poch, Katharina C. Kähler, Michael Weichenthal, Ralf Gutzmer, Lucie Heinzerling, Carsten Weishaupt, Peter Mohr, Kai-Martin Thoms, Berenice Lang, Bastian Schilling, Sebastian Haferkamp, Michael Sachse, Julia Welzel, Franziska Jochims, Ulrike Raap, Gaston Schley, Patrick Terheyden, Edgar Dippel, Christoph Pöttgen, Jürgen C. Becker, Alpaslan Tasdogan, Teresa Amaral, Lena Nanz, Ulrike Leiter
- Introduction
For rare skin cancers, few data exist on the outcome of systemic therapies, particularly immune checkpoint inhibition (ICI). The present study analysed the real-world use of different systemic therapies including ICI, and its outcome in patients with advanced rare skin cancers.
Methods
This retrospective multicenter study included patients who received systemic therapy for advanced, non-resectable cutaneous angiosarcoma (AS), Kaposi sarcoma (KS), pleomorphic dermal sarcoma (PDS), or cutaneous adnexal carcinoma (CAC). Study endpoints were best overall response (BOR), progression-free survival (PFS) and overall survival (OS).
Results
209 patients (77 AS; 81 KS; 14 PDS; and 37 CAC) from 30 centers were included. As first-line treatment AS and KS patients predominantly received chemotherapy (77.9 %; 63.0 %), while PDS and CAC patients mostly received ICI (64.4 %; 43.2 %). BOR in first-line across all therapy types was 65.5 % in KS, 50.0 % in PDS, 41.6 % in AS, and 10.8 %Introduction
For rare skin cancers, few data exist on the outcome of systemic therapies, particularly immune checkpoint inhibition (ICI). The present study analysed the real-world use of different systemic therapies including ICI, and its outcome in patients with advanced rare skin cancers.
Methods
This retrospective multicenter study included patients who received systemic therapy for advanced, non-resectable cutaneous angiosarcoma (AS), Kaposi sarcoma (KS), pleomorphic dermal sarcoma (PDS), or cutaneous adnexal carcinoma (CAC). Study endpoints were best overall response (BOR), progression-free survival (PFS) and overall survival (OS).
Results
209 patients (77 AS; 81 KS; 14 PDS; and 37 CAC) from 30 centers were included. As first-line treatment AS and KS patients predominantly received chemotherapy (77.9 %; 63.0 %), while PDS and CAC patients mostly received ICI (64.4 %; 43.2 %). BOR in first-line across all therapy types was 65.5 % in KS, 50.0 % in PDS, 41.6 % in AS, and 10.8 % in CAC. BOR for ICI was 66.6 % for PDS, 58.3 % for AS, 33.3 % for KS, and 4.3 % for CAC, irrespective of treatment line. 1-year PFS rate upon any first-line therapy was 70.7 % for PDS, 45.7 % for KS, 25.6 % for AS, and 18.5 % for CAC (p < 0.001). 1-year tumor-specific OS rate was 97.3 % in KS, 84.2 % in AS, 67.7 % in PDS, and 65.4 % in CAC (p < 0.001).
Conclusions
Type and outcome of systemic therapy differed between cancer entities. Efficacy of ICI was high in PDS and AS, moderate in KS, and low in CAC. Patients with advanced CAC revealed an extremely poor prognosis regardless of the type of therapy used.…
